Deng Ji, Liu Ze-Min, Zhu Kai-Rong, Cui Gui-Ling, Liu Lin-Xia, Yan Yu-Hang, Ning Xiang-Li, Yu Zhu-Jun, Li Guo-Bo, Qi Qing-Rong
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Bioorg Chem. 2023 Jun;135:106487. doi: 10.1016/j.bioorg.2023.106487. Epub 2023 Mar 23.
SIRT5 has been implicated in various physiological processes and human diseases, including cancer. Development of new highly potent, selective SIRT5 inhibitors is still needed to investigate disease-related mechanisms and therapeutic potentials. We here report new ε-N-thioglutaryllysine derivatives, which were designed according to SIRT5-catalysed deacylation reactions. These ε-N-thioglutaryllysine derivatives displayed potent SIRT5 inhibition, of which the potential photo-crosslinking derivative 8 manifested most potent inhibition with an IC value of 120 nM to SIRT5, and low inhibition to SIRT1-3 and SIRT6. The enzyme kinetic assays revealed that the ε-N-thioglutaryllysine derivatives inhibit SIRT5 by lysine-substrate competitive manner. Co-crystallographic analyses demonstrated that 8 binds to occupy the lysine-substate binding site by making hydrogen-bonding and electrostatic interactions with SIRT5-specific residues, and is likely positioned to react with NAD and form stable thio-intermediates. Compound 8 was observed to have low photo-crosslinking probability to SIRT5, possibly due to inappropriate position of the diazirine group as observed in SIRT5:8 crystal structure. This study provides useful information for developing drug-like inhibitors and cross-linking chemical probes for SIRT5-related studies.
SIRT5与包括癌症在内的多种生理过程和人类疾病有关。仍需要开发新型高效、选择性的SIRT5抑制剂来研究疾病相关机制和治疗潜力。我们在此报告了新的ε-N-硫代谷氨酰赖氨酸衍生物,它们是根据SIRT5催化的脱酰基反应设计的。这些ε-N-硫代谷氨酰赖氨酸衍生物表现出对SIRT5的有效抑制作用,其中潜在的光交联衍生物8对SIRT5表现出最有效的抑制作用,IC值为120 nM,而对SIRT1-3和SIRT6的抑制作用较低。酶动力学分析表明,ε-N-硫代谷氨酰赖氨酸衍生物以赖氨酸底物竞争方式抑制SIRT5。共结晶分析表明,8通过与SIRT5特异性残基形成氢键和静电相互作用来占据赖氨酸亚态结合位点,并可能与NAD反应形成稳定的硫代中间体。观察到化合物8与SIRT5的光交联概率较低,这可能是由于在SIRT5:8晶体结构中观察到的重氮丙啶基团位置不合适所致。本研究为开发用于SIRT5相关研究的类药物抑制剂和交联化学探针提供了有用信息。